A Study to Evaluate CRB-701 Compared to Investigator’s Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

​ Conditions: Oropharyngeal Carcinoma (OPC)

Interventions: Drug: CRB-701; Drug: capcitabine; Drug: Cetuximab (EGFR inhibitor); Drug: Docetaxel

Sponsors: Corbus Pharmaceuticals Inc.; CSPC Megalith Biopharmaceutical Co.,Ltd.

Not yet recruiting Conditions: Oropharyngeal Carcinoma (OPC)
Interventions: Drug: CRB-701; Drug: capcitabine; Drug: Cetuximab (EGFR inhibitor); Drug: Docetaxel
Sponsors: Corbus Pharmaceuticals Inc.; CSPC Megalith Biopharmaceutical Co.,Ltd.
Not yet recruiting